Breakthrough for NASH Drug Development Needs Combination Therapy & Reliable Composite Surrogate Endpoint

Time: 8:30 am
day: Conference Day 2

Details:

  • Delving into NASH prevalence and the market size
  • Elucidating the ways to tackle the challenges in developing an effective NASH drug 
  • Key regulatory considerations for combination therapy and navigating regulatory approval pathways

Speakers: